Soleno Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Soleno Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-12.9%

Buyback Yield

Total Shareholder Yield	-12.9%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Nov 08

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 10

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Mar 08

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Sep 20

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Aug 26

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Aug 12

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Jul 20

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

May 10

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Jan 24

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Jun 02

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Mar 23

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SLNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLNO's dividend payments have been increasing.

Dividend Yield vs Market

Soleno Therapeutics Dividend Yield vs Market

How does SLNO dividend yield compare to the market?
Segment	Dividend Yield
Company (SLNO)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.4%
Industry Average (Biotechs)	2.4%
Analyst forecast (SLNO) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate SLNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLNO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SLNO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLNO has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/02 02:26
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Soleno Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Kristen Kluska	Cantor Fitzgerald & Co.
François Brisebois	Craig-Hallum Capital Group LLC

Soleno Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

New major risk - Shareholder dilution

President recently sold US$966k worth of stock

Forecast to breakeven in 2027

Soleno Therapeutics, Inc. announced that it expects to receive $200 million in funding

Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Forecast to breakeven in 2026

Price target increased by 8.0% to US$73.57

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

President recently sold US$1.1m worth of stock

President recently sold US$5.5m worth of stock

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

No longer forecast to breakeven

President recently sold US$5.8m worth of stock

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

President recently sold US$800k worth of stock

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Independent Chairman exercised options to buy US$2.6m worth of stock.

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

President recently sold US$785k worth of stock

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Price target increased by 19% to US$60.17

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Forecast to breakeven in 2026

Vice President of Clinical Operations notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

President recently sold US$1.5m worth of stock

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Price target increased by 23% to US$45.67

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

New major risk - Shareholder dilution

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

New major risk - Financial position

No longer forecast to breakeven

No longer forecast to breakeven

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Forecast to breakeven in 2025

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Price target decreased to US$9.00

Insufficient new directors

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Insufficient new directors

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Insufficient new directors

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Price target decreased to US$5.00

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Price target lowered to US$7.00

New 90-day low: US$1.38

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: US$2.74